CA3188636A1 - Novel psilocin derivatives having prodrug properties - Google Patents
Novel psilocin derivatives having prodrug propertiesInfo
- Publication number
- CA3188636A1 CA3188636A1 CA3188636A CA3188636A CA3188636A1 CA 3188636 A1 CA3188636 A1 CA 3188636A1 CA 3188636 A CA3188636 A CA 3188636A CA 3188636 A CA3188636 A CA 3188636A CA 3188636 A1 CA3188636 A1 CA 3188636A1
- Authority
- CA
- Canada
- Prior art keywords
- psilocin
- ch2ch2
- derivative according
- disorder
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102020121965.2 | 2020-08-21 | ||
| DE102020121965.2A DE102020121965A1 (de) | 2020-08-21 | 2020-08-21 | Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften |
| US202063118842P | 2020-11-27 | 2020-11-27 | |
| US63/118,842 | 2020-11-27 | ||
| PCT/EP2021/073303 WO2022038299A1 (en) | 2020-08-21 | 2021-08-23 | Novel psilocin derivatives having prodrug properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188636A1 true CA3188636A1 (en) | 2022-02-24 |
Family
ID=77739049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188636A Pending CA3188636A1 (en) | 2020-08-21 | 2021-08-23 | Novel psilocin derivatives having prodrug properties |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230295086A1 (https=) |
| EP (1) | EP4200279A1 (https=) |
| JP (1) | JP2023538402A (https=) |
| KR (1) | KR20230054397A (https=) |
| CN (2) | CN116075499B (https=) |
| AU (1) | AU2021328726A1 (https=) |
| BR (1) | BR112023003153A2 (https=) |
| CA (1) | CA3188636A1 (https=) |
| CO (1) | CO2023003282A2 (https=) |
| GB (2) | GB2632056B (https=) |
| IL (1) | IL300455A (https=) |
| MX (1) | MX2023002133A (https=) |
| WO (1) | WO2022038299A1 (https=) |
| ZA (1) | ZA202301693B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024026574A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| WO2024026573A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US12414936B2 (en) * | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| US12343328B2 (en) | 2020-12-09 | 2025-07-01 | Caamtech, Inc. | Dialkyl tryptamines and their therapeutic uses |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| WO2023023347A1 (en) * | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Prodrugs and derivatives of psilocin and uses thereof |
| EP4452939A4 (en) * | 2021-12-24 | 2025-12-10 | Kuleon Llc | SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| US11707447B1 (en) | 2022-03-18 | 2023-07-25 | Enveric Biosciences Canada Inc. | C4-carbonothioate-substituted tryptamine derivatives and methods of using |
| EP4493544A4 (en) * | 2022-03-18 | 2026-03-04 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE |
| WO2023201293A2 (en) * | 2022-04-13 | 2023-10-19 | Caamtech, Inc. | Tryptamine derivatives |
| EP4522167A1 (en) * | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| WO2023219789A1 (en) * | 2022-05-10 | 2023-11-16 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| WO2024055106A1 (en) * | 2022-09-12 | 2024-03-21 | Bionxt Solutions Inc. | Amino acid and carbohydrate psilocin derivatives |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| EP4592276A1 (en) | 2024-01-29 | 2025-07-30 | Universität Heidelberg | Novel acyloxymethyl prodrugs of psilocin and related 4-hydroxytryptamines obtained by an efficient synthetic approach |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| CH386442A (de) | 1959-03-18 | 1965-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer 7-Aza-benzimidazole |
| AU2005300045A1 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| JP2010507585A (ja) * | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換インドール |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| CA3052974A1 (en) * | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2023023347A1 (en) * | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Prodrugs and derivatives of psilocin and uses thereof |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US20250066394A1 (en) * | 2023-08-25 | 2025-02-27 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
-
2021
- 2021-08-23 GB GB2412449.7A patent/GB2632056B/en active Active
- 2021-08-23 CN CN202180051296.8A patent/CN116075499B/zh active Active
- 2021-08-23 AU AU2021328726A patent/AU2021328726A1/en active Pending
- 2021-08-23 EP EP21769676.4A patent/EP4200279A1/en active Pending
- 2021-08-23 IL IL300455A patent/IL300455A/en unknown
- 2021-08-23 GB GB2304067.8A patent/GB2613993B/en active Active
- 2021-08-23 BR BR112023003153A patent/BR112023003153A2/pt unknown
- 2021-08-23 US US18/021,243 patent/US20230295086A1/en active Pending
- 2021-08-23 CN CN202510790017.XA patent/CN120904096A/zh active Pending
- 2021-08-23 WO PCT/EP2021/073303 patent/WO2022038299A1/en not_active Ceased
- 2021-08-23 JP JP2023512327A patent/JP2023538402A/ja active Pending
- 2021-08-23 KR KR1020237008542A patent/KR20230054397A/ko active Pending
- 2021-08-23 CA CA3188636A patent/CA3188636A1/en active Pending
- 2021-08-23 MX MX2023002133A patent/MX2023002133A/es unknown
-
2023
- 2023-02-10 ZA ZA2023/01693A patent/ZA202301693B/en unknown
- 2023-03-16 CO CONC2023/0003282A patent/CO2023003282A2/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024026574A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| WO2024026573A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2632056A (en) | 2025-01-22 |
| WO2022038299A1 (en) | 2022-02-24 |
| EP4200279A1 (en) | 2023-06-28 |
| GB202412449D0 (en) | 2024-10-09 |
| JP2023538402A (ja) | 2023-09-07 |
| GB2613993A (en) | 2023-06-21 |
| ZA202301693B (en) | 2026-01-28 |
| IL300455A (en) | 2023-04-01 |
| GB2613993B (en) | 2024-10-09 |
| MX2023002133A (es) | 2023-05-12 |
| GB2632056B (en) | 2025-04-16 |
| AU2021328726A1 (en) | 2023-03-02 |
| CN120904096A (zh) | 2025-11-07 |
| KR20230054397A (ko) | 2023-04-24 |
| BR112023003153A2 (pt) | 2023-04-04 |
| US20230295086A1 (en) | 2023-09-21 |
| CN116075499B (zh) | 2025-07-25 |
| CO2023003282A2 (es) | 2023-04-17 |
| CN116075499A (zh) | 2023-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230295086A1 (en) | Novel psilocin derivatives having prodrug properties | |
| EP3336097B1 (en) | Preparation of the non-crystalline form of obeticholic acid | |
| US8829196B2 (en) | TRPA1 antagonists | |
| US20230286975A1 (en) | Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof | |
| JP2005504042A (ja) | γセクレターゼインヒビターのようなスルホンアミド誘導体 | |
| CN106456618A (zh) | 普多比啶类似物，其制备及用途 | |
| US7091354B2 (en) | Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto | |
| JP2021531303A (ja) | エラゴリクスナトリウム組成物及び方法 | |
| CN117642396A (zh) | αVβ6和αVβ1整联蛋白抑制剂及其用途 | |
| EA051598B1 (ru) | Новые производные псилоцина, обладающие свойствами пролекарств | |
| BR122026001062A2 (pt) | Derivados de psilocina que apresentam propriedades pró-fármaco, seu uso e seu método de produção | |
| MXPA03011594A (es) | Un proceso para preparar paroxetina hc1 que limita la formacion de compuestos color rosa. | |
| EP4596538A1 (en) | Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method | |
| US8710078B2 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride | |
| HUE028550T2 (en) | Polymorphs of 6- (Piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride | |
| WO2025031304A1 (en) | Bilobalide derivative compounds for treating neurological diseases and cancers | |
| WO2022191092A1 (ja) | キノリン化合物、ｈｎｍｔ阻害剤、及びａｄｈｄ、ナルコレプシー又はアルツハイマーの予防・治療剤 | |
| US10550115B2 (en) | 1, 4, 8-triazaphenanthrene derivatives for the treatment of neurodegenerative disorders | |
| WO2024212248A1 (en) | Substituted alkanoic-diacids compound and composition and use thereof | |
| CN118525011A (zh) | 一种吗啉基喹唑啉类化合物、其制备方法及应用 | |
| HK40078313A (en) | Analogs of pridopidine, their preparation and use | |
| HK1192546B (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride | |
| NZ620864B2 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250722 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250924 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250924 |